Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label infant study of 10-valent pneumococcal conjugate vaccine co-administered with Infanrix hexa in Vietnam
2012-000162-38Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of 10-valent pneumococcal conjugate vaccine and pertussis filamentous haemagglutinin in pneumococcal disease, sponsored by GSK. Primary endpoints: Occurrence of grade 3 solicited adverse events and Occurrence of grade 3 unsolicited adverse events.
02
Drugs
10-valent pneumococcal conjugate vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2012-000162-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000162-38.